Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Portfolio Pulse from
Ensysce Biosciences has dosed the first subjects in its PF614-MPAR trial, a breakthrough therapy for overdose protection. The trial is supported by a $14 million award from NIDA, with interim data expected in Q1 2025.
November 26, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ensysce Biosciences has initiated dosing in its PF614-MPAR trial, a significant step for its breakthrough therapy aimed at overdose protection. The trial is supported by a $14 million award from NIDA, with early interim data anticipated in Q1 2025.
The initiation of dosing in the PF614-MPAR trial marks a significant milestone for Ensysce Biosciences, indicating progress in their breakthrough therapy development. The $14 million award from NIDA provides financial support, and the FDA's Breakthrough Therapy designation suggests potential for expedited development and review. These factors are likely to positively influence investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100